Safety, Tolerability, Efficacy of MTP-131 for Treatment of Mitochondrial Disease in Subjects From the MMPOWER Study
Source · ClinicalTrials.gov: elamipretide
TLDR
ClinicalTrials.gov lists a completed study evaluating elamipretide in people with primary mitochondrial myopathy. The randomized, double-blind, placebo-controlled crossover study screened 32 subjects to assess safety, tolerability, pharmacokinetics, and efficacy; the excerpt provides no results.
- 01The study focused on subjects from the MMPOWER study.
- 02Investigators screened 32 subjects with primary mitochondrial myopathy.
- 03Completed status does not establish safety or efficacy; no findings are included in the excerpt.
Why it matters Editorial
The listing documents clinical evaluation of elamipretide for mitochondrial disease, but the excerpt does not support conclusions about its benefits or risks.
Summary generated with AI and reviewed by an editor. The original source governs; summaries can contain errors. Information only — not medical advice. Full disclaimer.
ClinicalTrials.gov: elamipretide
ClinicalTrials.gov: elamipretide
ClinicalTrials.gov: elamipretide
ClinicalTrials.gov: elamipretide